Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro

Anna Rosell, Ken Arai, Josephine Lok, Tongrong He, Shuzhen Guo, Miriam Navarro, Joan Montaner, Zvonimir S Katusic, Eng H. Lo

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Endothelial progenitor cells (EPCs) may provide novel opportunities for therapeutic angiogenesis after ischemic diseases. However, it is unclear how the angiogenic potential of EPCs might be affected by an inflammatory environment. We examine how the potent cytokine interleukin-1β (IL-1β) affects angiovasculogenic responses in EPCs in culture. Mononuclear cells isolated from mouse spleen were plated on fibronectin-coated wells and grown in EGM-2MV media. Endothelial progenitor cells were phenotyped using multiple markers (UEA-Lectin, ac-LDL, CD133, CD34, vWillebrand Factor, Flk-1) and to identify the IL-1 Receptor-I. We quantified cell and colony counts and performed MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) and Matrigel assays, in vitro, under control and IL-1β (10ng mL) conditions. Endothelial progenitor cells exposed to IL-1β increased in the number of cells and colonies compared with untreated cells, without any effect on cell metabolic integrity. Furthermore, IL-1β treatment augmented EPC angiogenic function, significantly increasing the number of vessel-like structures in the Matrigel assay. An early phosphorylation of ERK1 2 occurred after IL-1β stimulation, and this pathway was inhibited if IL-1 Receptor-I was blocked. Our results suggest that IL-1β is a potent stimulator of in vitro angiogenesis through ERK signaling in mouse EPCs. Further studies are warranted to assess how interactions between proinflammatory environments and EPC responses may be leveraged to enhance therapeutic angiogenesis.

Original languageEnglish (US)
Pages (from-to)933-943
Number of pages11
JournalJournal of Cerebral Blood Flow and Metabolism
Volume29
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Interleukin-1
Interleukin-1 Receptors
Cell Count
In Vitro Techniques
Endothelial Progenitor Cells
Fibronectins
Lectins
Spleen
Cell Culture Techniques
Phosphorylation
Cytokines
Therapeutics

Keywords

  • Angiogenesis
  • Cytokine
  • MAP kinase
  • Neuroinflammation
  • Spleen
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro. / Rosell, Anna; Arai, Ken; Lok, Josephine; He, Tongrong; Guo, Shuzhen; Navarro, Miriam; Montaner, Joan; Katusic, Zvonimir S; Lo, Eng H.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 29, No. 5, 05.2009, p. 933-943.

Research output: Contribution to journalArticle

Rosell, Anna ; Arai, Ken ; Lok, Josephine ; He, Tongrong ; Guo, Shuzhen ; Navarro, Miriam ; Montaner, Joan ; Katusic, Zvonimir S ; Lo, Eng H. / Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro. In: Journal of Cerebral Blood Flow and Metabolism. 2009 ; Vol. 29, No. 5. pp. 933-943.
@article{862f479102d342f1a4d4023c4963ded3,
title = "Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro",
abstract = "Endothelial progenitor cells (EPCs) may provide novel opportunities for therapeutic angiogenesis after ischemic diseases. However, it is unclear how the angiogenic potential of EPCs might be affected by an inflammatory environment. We examine how the potent cytokine interleukin-1β (IL-1β) affects angiovasculogenic responses in EPCs in culture. Mononuclear cells isolated from mouse spleen were plated on fibronectin-coated wells and grown in EGM-2MV media. Endothelial progenitor cells were phenotyped using multiple markers (UEA-Lectin, ac-LDL, CD133, CD34, vWillebrand Factor, Flk-1) and to identify the IL-1 Receptor-I. We quantified cell and colony counts and performed MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) and Matrigel assays, in vitro, under control and IL-1β (10ng mL) conditions. Endothelial progenitor cells exposed to IL-1β increased in the number of cells and colonies compared with untreated cells, without any effect on cell metabolic integrity. Furthermore, IL-1β treatment augmented EPC angiogenic function, significantly increasing the number of vessel-like structures in the Matrigel assay. An early phosphorylation of ERK1 2 occurred after IL-1β stimulation, and this pathway was inhibited if IL-1 Receptor-I was blocked. Our results suggest that IL-1β is a potent stimulator of in vitro angiogenesis through ERK signaling in mouse EPCs. Further studies are warranted to assess how interactions between proinflammatory environments and EPC responses may be leveraged to enhance therapeutic angiogenesis.",
keywords = "Angiogenesis, Cytokine, MAP kinase, Neuroinflammation, Spleen, Stroke",
author = "Anna Rosell and Ken Arai and Josephine Lok and Tongrong He and Shuzhen Guo and Miriam Navarro and Joan Montaner and Katusic, {Zvonimir S} and Lo, {Eng H.}",
year = "2009",
month = "5",
doi = "10.1038/jcbfm.2009.17",
language = "English (US)",
volume = "29",
pages = "933--943",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro

AU - Rosell, Anna

AU - Arai, Ken

AU - Lok, Josephine

AU - He, Tongrong

AU - Guo, Shuzhen

AU - Navarro, Miriam

AU - Montaner, Joan

AU - Katusic, Zvonimir S

AU - Lo, Eng H.

PY - 2009/5

Y1 - 2009/5

N2 - Endothelial progenitor cells (EPCs) may provide novel opportunities for therapeutic angiogenesis after ischemic diseases. However, it is unclear how the angiogenic potential of EPCs might be affected by an inflammatory environment. We examine how the potent cytokine interleukin-1β (IL-1β) affects angiovasculogenic responses in EPCs in culture. Mononuclear cells isolated from mouse spleen were plated on fibronectin-coated wells and grown in EGM-2MV media. Endothelial progenitor cells were phenotyped using multiple markers (UEA-Lectin, ac-LDL, CD133, CD34, vWillebrand Factor, Flk-1) and to identify the IL-1 Receptor-I. We quantified cell and colony counts and performed MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) and Matrigel assays, in vitro, under control and IL-1β (10ng mL) conditions. Endothelial progenitor cells exposed to IL-1β increased in the number of cells and colonies compared with untreated cells, without any effect on cell metabolic integrity. Furthermore, IL-1β treatment augmented EPC angiogenic function, significantly increasing the number of vessel-like structures in the Matrigel assay. An early phosphorylation of ERK1 2 occurred after IL-1β stimulation, and this pathway was inhibited if IL-1 Receptor-I was blocked. Our results suggest that IL-1β is a potent stimulator of in vitro angiogenesis through ERK signaling in mouse EPCs. Further studies are warranted to assess how interactions between proinflammatory environments and EPC responses may be leveraged to enhance therapeutic angiogenesis.

AB - Endothelial progenitor cells (EPCs) may provide novel opportunities for therapeutic angiogenesis after ischemic diseases. However, it is unclear how the angiogenic potential of EPCs might be affected by an inflammatory environment. We examine how the potent cytokine interleukin-1β (IL-1β) affects angiovasculogenic responses in EPCs in culture. Mononuclear cells isolated from mouse spleen were plated on fibronectin-coated wells and grown in EGM-2MV media. Endothelial progenitor cells were phenotyped using multiple markers (UEA-Lectin, ac-LDL, CD133, CD34, vWillebrand Factor, Flk-1) and to identify the IL-1 Receptor-I. We quantified cell and colony counts and performed MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) and Matrigel assays, in vitro, under control and IL-1β (10ng mL) conditions. Endothelial progenitor cells exposed to IL-1β increased in the number of cells and colonies compared with untreated cells, without any effect on cell metabolic integrity. Furthermore, IL-1β treatment augmented EPC angiogenic function, significantly increasing the number of vessel-like structures in the Matrigel assay. An early phosphorylation of ERK1 2 occurred after IL-1β stimulation, and this pathway was inhibited if IL-1 Receptor-I was blocked. Our results suggest that IL-1β is a potent stimulator of in vitro angiogenesis through ERK signaling in mouse EPCs. Further studies are warranted to assess how interactions between proinflammatory environments and EPC responses may be leveraged to enhance therapeutic angiogenesis.

KW - Angiogenesis

KW - Cytokine

KW - MAP kinase

KW - Neuroinflammation

KW - Spleen

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=65549097702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549097702&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2009.17

DO - 10.1038/jcbfm.2009.17

M3 - Article

VL - 29

SP - 933

EP - 943

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 5

ER -